RESEARCH TRIANGLE PARK, N.C., Feb. 12, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (GTHX) (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the independent Data Monitoring ...
Top-line phase III data from G1 Therapeutics Inc.’s pivotal Preserve 2 study of Cosela (trilaciclib) in treating metastatic triple-negative breast cancer missed its primary endpoint of overall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results